Autoantibodies to mesothelin in infertility

Cancer Epidemiology Biomarkers and Prevention

Volumn 20, Issue 9, 2011, Pages 1970-1978

  Luborsky, Judith L ^a   Yu, Yi ^a   Edassery, Seby L ^a   Jaffar, Jade ^b,c   Yip, Yuan Yee ^b,d   Liu, Pu ^b   Hellstrom, Karl Eric ^b   Hellstrom, Ingegerd ^b  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF SYDNEY   (Australia)

^d Meso Scale Discovery   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; MESOTHELIN; MESOTHELIN ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; CANCER RISK; CONTROLLED STUDY; ENDOMETRIOSIS; FEMALE; FEMALE INFERTILITY; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; OVARY CANCER; OVARY CYST; OVARY FUNCTION; OVARY INSUFFICIENCY; OVARY TUMOR; PREMATURE OVARIAN FAILURE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; CASE-CONTROL STUDIES; FEMALE; GPI-LINKED PROTEINS; HUMANS; INFERTILITY, FEMALE; MIDDLE AGED; OVARIAN NEOPLASMS; YOUNG ADULT;

EID: 80052543935     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-11-0139     Document Type: Article

References (86)

1. Tortolero-Luna G., Mitchell M.F. The epidemiology of ovarian cancer. J Cell Biochem Suppl 1995;23:200-207 (Pubitemid 26032876)
2. Venn A., Healy D., McLachlan R. Cancer risks associated with the diagnosis of infertility. Best Pract Res Clin Obstet Gynaecol 2003;17:343-367 (Pubitemid 36647990)
3. Runnebaum I.B., Stickeler E. Epidemiological and molecular aspects of ovarian cancer risk. J Cancer Res Clin Oncol 2001;127:73-79
4. Ness R.B., Cramer D.W., Goodman M.T., Kjaer S.K., Mallin K., Mosgaard B.J., et al. Infertility, fertility drugs, and ovarian cancer: A pooled analysis of case-control studies. Am J Epidemiol 2002;155:217-224 (Pubitemid 34117299)
5. Rossing M.A., Tang M.T., Flagg E.W., Weiss L.K., Wicklund K.G. A case-control study of ovarian cancer in relation to infertility and the use of ovulation-inducing drugs. Am J Epidemiol 2004;160:1070-1078 (Pubitemid 39557459)
6. Kallen B., Finnstrom O., Lindam A., Nilsson E., Nygren K.G., Otterblad Olausson P. Malignancies among women who gave birth after in vitro fertilization. Hum Reprod 2011;26:253-258
7. Brinton L.A., Westhoff C.L., Scoccia B., Lamb E.J., Althuis M.D., Mabie J.E., et al. Causes of infertility as predictors of subsequent cancer risk. Epidemiology 2005;16:500-507 (Pubitemid 40847834)
8. Brinton L.A., Lamb E.J., Moghissi K.S., Scoccia B., Althuis M.D., Mabie J.E., et al. Ovarian cancer risk associated with varying causes of infertility. Fertil Steril 2004;82:405-414 (Pubitemid 39092042)
9. Kamel R.M. Management of the infertile couple: An evidence-based protocol. Reprod Biol Endocrinol 2010;8:21.
10. Sunderam S., Chang J., Flowers L., Kulkarni A., Sentelle G., Jeng G., et al. Assisted reproductive technology surveillance-United States, 2006. MMWR Surveill Summ 2009;58:1-25.
11. Molinaro T.A., Shaunik A., Lin K., Sammel M.D., Barnhart K.T. A strict infertility diagnosis has poor agreement with the clinical diagnosis entered into the Society for Assisted Reproductive Technology registry. Fertil Steril 2009;92:2088-2090
12. Luborsky J., Sowers M., Gold E., Meyers P., Eckhold H., Santoro N. Premature menopause (POF) in a multi-ethnic population study of the menopause transition. 4th International Symposium on Women's Health and Menopause, pp. abstract. Washington, DC;2001.
13. Goswami D., Conway G.S. Premature ovarian failure. Hum Reprod Update 2005;11:391-410. (Pubitemid 40895467)
14. Santoro N. Research on the mechanisms of premature ovarian failure. J Soc Gynecol Investig 2001;8:S10-S12
15. Cramer D.W. Epidemiologic aspects of early menopause and ovarian cancer. Ann N Y Acad Sci 1990;592:363-375 (Pubitemid 20273238)
16. Cramer D.W., Hutchison G.B., Welch W.R., Scully R.E., Ryan K.J. Determinants of ovarian cancer risk. I. Reproductive experiences and family history. J Natl Cancer Inst 1983;71:711-716 (Pubitemid 14232384)
17. Cramer D.W., Welch W.R., Cassells S., Scully R.E. Mumps, menarche, menopause, and ovarian cancer. Am J Obstet Gynecol 1983;147:1-6. (Pubitemid 13001533)
18. Smith E.R., Xu X.X. Ovarian ageing, follicle depletion, and cancer: A hypothesis for the aetiology of epithelial ovarian cancer involving follicle depletion. Lancet Oncol 2008;9:1108-1111
19. Vanderhyden B.C. Loss of ovarian function and the risk of ovarian cancer. Cell Tissue Res 2005;322:117-124 (Pubitemid 41677662)
20. Venn A., Watson L., Bruinsma F., Giles G., Healy D. Risk of cancer after use of fertility drugs with in vitro fertilisation. Lancet 1999;354:1586-1590 (Pubitemid 29515949)
21. Luborsky J., Llanes B., Davies S., Binor Z., Radwanska E., Pong R. Ovarian autoimmunity: Greater frequency of autoantibodies in premature menopause and unexplained infertility than in the general population. Clin Immunol 1999;90:368-374 (Pubitemid 29159622)
22. Luborsky J. Ovarian autoimmune disease and ovarian autoantibodies. J Womens Health Gend Based Med 2002;11:585-599
23. Luborsky J.L., Visintin I., Boyers S., Asare T., Caldwell B., DeCherney A. Ovarian antibodies detected by immobilized antigen immunoassay in patients with premature ovarian failure. J Clin Endocrinol Metab 1990;70:69-75.
24. Pires E.S., Khole V.V. A block in the road to fertility: Autoantibodies to heat-shock protein 90-beta in human ovarian autoimmunity. Fertil Steril 2009;92:1395-1409
25. Sundblad V., Bussmann L., Chiauzzi V.A., Pancholi V., Charreau E.H. Alpha-enolase: A novel autoantigen in patients with premature ovarian failure. Clin Endocrinol (Oxf) 2006;65:745-751 (Pubitemid 44772354)
26. Forges T., Monnier-Barbarino P., Faure G.C., Bene M.C. Autoimmunity and antigenic targets in ovarian pathology. Hum Reprod Update 2004;10:163-175 (Pubitemid 38523297)
27. Meyer W.R., Lavy G., DeCherney A.H., Visintin I., Economy K., Luborsky J.L. Evidence of gonadal and gonadotropin antibodies in women with a suboptimal ovarian response to exogenous gonadotropin. Obstet Gynecol 1990;75:795-799 (Pubitemid 20139160)
28. Creus M., Penarrubia J., Fabregues F., Vidal E., Carmona F., Casamitjana R., et al. Day 3 serum inhibin B and FSH and age as predictors of assisted reproduction treatment outcome. Hum Reprod 2000;15:2341-2346
29. Luborsky J., Roussev R., Coulam C. Ovarian antibodies, FSH and inhibin are independent markers associated with unexplained infertility. Human Reprod 2000;15:1046-1051 (Pubitemid 30251297)
30. Gnjatic S., Ritter E., Buchler M.W., Giese N.A., Brors B., Frei C., et al. Seromic profiling of ovarian and pancreatic cancer. Proc Natl Acad Sci U S A 2010;107:5088-5093
31. Reuschenbach M., Von Knebel Doeberitz M., Wentzensen N. A systematic review of humoral immune responses against tumor antigens. Cancer Immunol Immunother 2009;58:1535-1544
32. Bei R., Masuelli L., Palumbo C., Modesti M., Modesti A. A common repertoire of autoantibodies is shared by cancer and autoimmune disease patients: Inflammation in their induction and impact on tumor growth. Cancer Lett 2009;281:8-23.
33. Stockert E., Jager E., Chen Y.T., Scanlan M.J., Gout I., Karbach J., et al. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 1998;187:1349-1354 (Pubitemid 28189124)
34. Nesterova M., Johnson N., Cheadle C., Cho-Chung YS. Autoantibody biomarker opens a new gateway for cancer diagnosis. Biochim Biophys Acta 2006;1762:398-403.
35. Tan E.M., Zhang J. Autoantibodies to tumor-associated antigens: Reporters from the immune system. Immunol Rev 2008;222:328-340 (Pubitemid 351430373)
36. Barua A., Bradaric M.J., Kebede T., Espinosa S., Edassery S.L., Bitterman P., et al. Anti-ovarian and anti-tumor antibodies in women with ovarian cancer. Am J Reprod Immunol 2007;57:243-249 (Pubitemid 46394836)
37. Luborsky J.L., Barua A., Shatavi S.V., Kebede T., Abramowicz J., Rotmensch J. Anti-tumor antibodies in ovarian cancer. Am J Reprod Immunol 2005;54:55-62. (Pubitemid 41087067)
38. Erkanli A., Taylor D.D., Dean D., Eksir F., Egger D., Geyer J., et al. Application of Bayesian modeling of autologous antibody responses against ovarian tumor-associated antigens to cancer detection. Cancer Res 2006;66:1792-1798 (Pubitemid 43259965)
39. Ramirez-Montagut T., Turk M.J., Wolchok J.D., Guevara-Patino J.A., Houghton A.N. Immunity to melanoma: Unraveling the relation of tumor immunity and autoimmunity. Oncogene 2003;22:3180-3187 (Pubitemid 36713770)
40. Uchi H., Stan R., Turk M.J., Engelhorn M.E., Rizzuto G.A., Goldberg S.M., et al. Unraveling the complex relationship between cancer immunity and autoimmunity: Lessons from melanoma and vitiligo. Adv Immunol 2006;90:215-241 (Pubitemid 43765798)
41. Prehn R.T., Prehn L.M. The flip side of immune surveillance: Immune dependency. Immunol Rev 2008;222:341-356 (Pubitemid 351430371)
42. Prehn R.T. An immune reaction may be necessary for cancer development. Theor Biol Med Model 2006;3:6.
43. Rosen D.G., Wang L., Atkinson J.N., Yu Y., Lu K.H., Diamandis E.P., et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol 2005;99:267-277 (Pubitemid 41502830)
44. Scholler N., Fu N., Yang Y., Ye Z., Goodman G.E., Hellstrom K.E., et al. Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc Natl Acad Sci U S A 1999;96:11531-11536 (Pubitemid 29487415)
45. McIntosh M.W., Drescher C., Karlan B., Scholler N., Urban N., Hellstrom K.E., et al. Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. Gynecol Oncol 2004;95:9-15. (Pubitemid 39286271)
46. Palmer C., Duan X., Hawley S., Scholler N., Thorpe J.D., Sahota R.A., et al. Systematic evaluation of candidate blood markers for detecting ovarian cancer. PLoS One 2008;3:e2633.
47. Ho M., Hassan R., Zhang J., Wang Q.C., Onda M., Bera T., et al. Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients. Clin Cancer Res 2005;11:3814-3820 (Pubitemid 40685601)
48. HellstromI., Friedman E., Verch T., Yang Y., Korach J., Jaffar J., et al. Anti-mesothelin antibodies and circulating mesothelin relate to the clinical state in ovarian cancer patients. Cancer Epidemiol Biomarkers Prev 2008;17:1520-1526
49. Broekmans F.J., Fauser B.C. Diagnostic criteria for polycystic ovarian syndrome. Endocrine 2006;30:3-11. (Pubitemid 46020324)
50. Ng S.K., Wang D.I., Yap M.G. Application of destabilizing sequences on selection marker for improved recombinant protein productivity in CHO-DG44. Metab Eng 2007;9:304-316 (Pubitemid 46823903)
51. Hellstrom I., Raycraft J., Kanan S., Sardesai N.Y., Verch T., Yang Y., et al. Mesothelin variant 1 is released from tumor cells as a diagnostic marker. Cancer Epidemiol Biomarkers Prev 2006;15:1014-1020 (Pubitemid 43823532)
52. Johnston F.M., Tan M.C., Tan B.R. Jr., Porembka M.R., Brunt E.M., Linehan D.C., et al. Circulating mesothelin protein and cellular antimesothelin immunity in patients with pancreatic cancer. Clin Cancer Res 2009;15:6511-6518
53. Luborsky J.L., Thiruppathi P., Rivnay B., Roussev R., Coulam C., Radwanska E. Evidence for different aetiologies of low estradiol response to FSH: Age-related accelerated luteinization of follicles or presence of ovarian autoantibodies. Hum Reprod 2002;17:2641-2649 (Pubitemid 35174116)
54. Shatavi S.V., Llanes B., Luborsky J.L. Association of unexplained infertility with gonadotropin and ovarian antibodies. Am J Reprod Immunol 2006;56:286-291 (Pubitemid 44669324)
55. Edassery S.L., Shatavi S.V., Kunkel J.P., Hauer C., Brucker C., Penumatsa K., et al. Autoantigens in ovarian autoimmunity associated with unexplained infertility and premature ovarian failure. Fertil Steril 2010;94:2636-2641
56. Taylor D.D., Gercel-Taylor C., Parker L.P. Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer. Gynecol Oncol 2009;115:112-120
57. Jager E., Stockert E., Zidianakis Z., Chen Y.T., Karbach J., Jager D., et al. Humoral immune responses of cancer patients against "Cancer- Testis" antigen NY-ESO-1: Correlation with clinical events. Int J Cancer 1999;84:506-510
58. Gnjatic S., Wheeler C., Ebner M., Ritter E., Murray A., Altorki N.K., et al. Seromic analysis of antibody responses in non-small cell lung cancer patients and healthy donors using conformational protein arrays. J Immunol Methods 2009;341:50-58
59. Hassan R., Remaley A.T., Sampson M.L., Zhang J., Cox D.D., Pingpank J., et al. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res 2006;12:447-453 (Pubitemid 43166134)
60. Hellstrom I., Hellstrom K.E. SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and/or each other. Adv Exp Med Biol 2008;622:15-21.
61. Monnier-Barbarino P., Forges T., Faure G.C., Bene M.C. [Ovarian autoimmunity and ovarian pathologies: antigenic targets and diagnostic significance]. J Gynecol Obstet Biol Reprod (Paris) 2005;34:649-657
62. Nezhat F., Datta M.S., Hanson V., Pejovic T., Nezhat C. The relationship of endometriosis and ovarian malignancy: A review. Fertil Steril 2008;90:1559-1570
63. Mandai M., Yamaguchi K., Matsumura N., Baba T., Konishi I. Ovarian cancer in endometriosis: Molecular biology, pathology, and clinical management. Int J Clin Oncol 2009;14:383-391
64. Salvador S., Gilks B., Kobel M., Huntsman D., Rosen B., Miller D. The fallopian tube: Primary site of most pelvic high-grade serous carcinomas. Int J Gynecol Cancer 2009;19:58-64.
65. Piek J.M., Van Diest P.J., Verheijen R.H. Ovarian carcinogenesis: An alternative hypothesis. Adv Exp Med Biol 2008;622:79-87.
66. Jensen A., Sharif H., Frederiksen K., Kjaer S.K. Use of fertility drugs and risk of ovarian cancer: Danish Population Based Cohort Study. BMJ 2009;338:b249.
67. Kobel M., Kalloger S.E., Boyd N., McKinney S., Mehl E., Palmer C., et al. Ovarian carcinoma subtypes are different diseases: Implications for biomarker studies. PLoS Med 2008;5:e232.
68. Marquez R.T., Baggerly K.A., Patterson A.P., Liu J., Broaddus R., Frumovitz M., et al. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res 2005;11:6116-6126 (Pubitemid 41262937)
69. Draghici S., Chatterjee M., Tainsky M.A. Epitomics: Serum screening for the early detection of cancer on microarrays using complex panels of tumor antigens. Expert Rev Mol Diagn 2005;5:735-743 (Pubitemid 41337468)
70. Gunawardana C.G., Memari N., Diamandis E.P. Identifying novel autoantibody signatures in ovarian cancer using high-density protein microarrays. Clin Biochem 2009;42:426-429
71. Tang L., Yang J., Ng S.K., Rodriguez N., Choi P.W., Vitonis A., et al. Autoantibody profiling to identify biomarkers of key pathogenic pathways in mucinous ovarian cancer. Eur J Cancer 2010;46:170-179
72. Frierson H.F. Jr., Moskaluk C.A., Powell S.M., Zhang H., Cerilli L.A., Stoler M.H., et al. Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas. Hum Pathol 2003;34:605-609 (Pubitemid 36750373)
73. Cramer D.W., O'Rourke D.J., Vitonis A.F., Matulonis U.A., Dijohnson D.A., Sluss P.M., et al. CA125 immune complexes in ovarian cancer patients with low CA125 concentrations. Clin Chem 2010;56:1889-1892
74. Croce M.V., Isla-Larrain M.T., Price M.R., Segal-Eiras A. Detection of circulating mammary mucin (Muc1) and MUC1 immune complexes (Muc1-CIC) in healthy women. Int J Biol Markers 2001;16:112-120 (Pubitemid 32755128)
75. De Visser K.E. Spontaneous immune responses to sporadic tumors: Tumor-promoting, tumor-protective or both?Cancer Immunol Immunother 2008;57:1531-1539
76. De Visser K.E., Korets L.V., Coussens L.M. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 2005;7:411-423 (Pubitemid 40719125)
77. De Visser K.E., Eichten A., Coussens L.M. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006;6:24-37. (Pubitemid 43053650)
78. Shearer W.T., Philpott G.W., Parker C.W. Stimulation of cells by antibody. Science 1973;182:1357-1359
79. Vlad A.M., Diaconu I., Gantt K.R. MUC1 in endometriosis and ovarian cancer. Immunol Res 2006;36:229-236 (Pubitemid 46398599)
80. Cramer D.W., Titus-Ernstoff L., McKolanis J.R., Welch W.R., Vitonis A.F., Berkowitz R.S., et al. Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev 2005;14:1125-1131 (Pubitemid 40656457)
81. Terry K.L., Titus-Ernstoff L., McKolanis J.R., Welch W.R., Finn O.J., Cramer D.W. Incessant ovulation, mucin 1 immunity, and risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev 2007;16:30-35 (Pubitemid 46174260)
82. Hermsen B.B., Verheijen R.H., Menko F.H., Gille J.J., Van Uffelen K., Blankenstein M.A., et al. Humoral immune responses to MUC1 in women with a BRCA1 or BRCA2 mutation. Eur J Cancer 2007;43:1556-1563 (Pubitemid 46891805)
83. Rabassa M.E., Croce M.V., Pereyra A., Segal-Eiras A. MUC1 expression and anti-MUC1 serum immune response in head and neck squamous cell carcinoma (HNSCC): A multivariate analysis. BMC Cancer 2006;6:253.
84. Fredrickson T.N. Ovarian tumors of the hen. Environ Health Perspect 1987;73:35-51.
85. Barua A., Bradaric M.J., Kebede T., Espionosa S., Edassery S.L., Bitterman P., et al. Anti-tumor and anti-ovarian autoantibodies in women with ovarian cancer. Am J Reprod Immunol 2007;57:243-249 (Pubitemid 46394836)
86. Yu Y., Edassery S.L., Barua A., Abramowicz J.S., Bahr J.M., Hellstrom I., et al. The hen model of human ovarian cancer develops anti-mesothelin autoantibodies in response to mesothelin expressing tumors. J Ovarian Research 2011;4:12 (July 29 2011).